KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of α-MSH without its pigmentation effects.
KPV has shown significant anti-inflammatory activity in preclinical studies, particularly in models of inflammatory bowel disease (IBD), colitis, and skin inflammation. It works by entering cells and interacting directly with inflammatory signaling pathways.
KPV is not FDA-approved for medical use. Research is primarily preclinical. It is available through compounding pharmacies for off-label use, commonly in oral, topical, or injectable forms.
Most evidence comes from animal models of colitis and dermatitis; human studies are needed.
KPV exerts its effects through intracellular anti-inflammatory pathways:
Study demonstrating KPV's anti-inflammatory effects in experimental colitis through NF-κB inhibition.
Research elucidating the intracellular mechanisms by which KPV suppresses inflammatory signaling cascades.
Comprehensive review of α-MSH-derived peptides including KPV and their therapeutic potential in inflammatory conditions.
If you're using a browser with advanced ad blocking security measures, the above study links may not work. You can copy the link and paste it into a new window.
Disclaimer: The information on this page was generated with the assistance of artificial intelligence and compiled from publicly available sources. While efforts are made to ensure accuracy, information may be incomplete, outdated, or incorrect and should not be relied upon as medical advice.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded drugs have not been approved by the FDA; have not been reviewed by the FDA for safety, efficacy, or quality; and have not been demonstrated to the FDA to be safe or effective for their intended use. The processes by which the compounded drugs are manufactured have not been reviewed by the FDA. FDA approved products containing semaglutide and tirzepatide are available.